Usher Syndrome Market to Witness Upsurge in Growth During the Forecast Period (2022-32) | Key Players – Sanofi, ProQR Therapeutics, Neurotech, Editas Medicine, Atsena Therapeutics, Nacuity

Usher Syndrome Market to Witness Upsurge in Growth During the Forecast Period (2022-32) | Key Players - Sanofi, ProQR Therapeutics, Neurotech, Editas Medicine, Atsena Therapeutics, Nacuity
Delveinsight Business Research LLP
As per DelveInsight, the Usher Syndrome market dynamics are anticipated to change in the coming years owing to the positive outcomes of some of the candidates in the developmental stage. Key players worldwide are involved in developing therapies for Usher Syndrome that are under different phases of clinical development and hold the potential to create a significant positive shift in the Usher Syndrome market size.

DelveInsight’s “Usher Syndrome Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Usher Syndrome market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Usher Syndrome market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Usher Syndrome Market

Usher Syndrome: An Overview

Usher syndrome is a group of inherited retinal degenerations characterized by both hearing loss and vision loss that worsens over time. The hearing loss is classified as sensorineural, which means that abnormalities of the inner ear cause it. The loss of vision is caused by an eye disease called retinitis pigmentosa (RP), which affects the layer of light-sensitive tissue at the back of the eye (the retina). Usher syndrome is also known as deafness-retinitis pigmentosa syndrome, Graefe-Usher syndrome, Hallgren syndrome, and retinitis pigmentosa-deafness syndrome.

Three main clinical types of Usher Syndrome have been characterized as; Type 1, Type 2, and Type 3. They are distinguished on the basis of the severity of the hearing loss, the presence or absence of vestibular dysfunction, and the age of onset of retinitis pigmentosa (RP).

Treatment and communication services may include hearing aids, assistive listening devices, cochlear implants, auditory (hearing) training, and/or learning sign language. Vitamin A may slow the progression of RP. Other potential treatments include such as gene therapy, drug-based therapy, and others.

Usher Syndrome Market Key Facts

  • The prevalence of Usher Syndrome varies from country to country; historically, it has been considered a rare disorder with a frequency of 1 per 25,000. However, recent European articles estimated it to be near 1 per 6000. Usher syndrome affects 1 in 12,500 in Germany.

  • According to NIH, “Usher syndrome affects around 4 to 17 in 100,000 people. Types 1 and 2 accounts for 90-95% of Usher syndrome in most countries. Certain genetic mutations resulting in type 1 Usher syndrome are more common among people of eastern and central European or French Acadian heritage.”

  • Type 1 is the most severe subtype of Usher syndrome and accounts for approximately 25–44% of all USH cases. Type 2 is the most common form of USH, representing over half of all cases. Type 3 represents only about 2-5 percent of all cases.

  • Usher syndrome types 1 and 2 account for approximately 10 percent of all cases of moderate to profound deafness in children.

  • As per DelveInsight, Usher Syndrome is more prominent in children than adults.

Usher Syndrome Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Usher Syndrome market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete detail of the Usher Syndrome market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.

Usher Syndrome Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders. 

The Report Covers the Usher Syndrome Epidemiology Segmented, by –

  • Prevalent Cases of Usher Syndrome

  • Age-specific Cases of Usher Syndrome

  • Subtype specific Cases of Usher Syndrome

  • Diagnosed and Treatable Cases of Usher Syndrome

Usher Syndrome Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Usher Syndrome market or expected to get launched during the study period. The analysis covers the Usher Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Usher Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How Usher Syndrome Market Will Evolve by 2032 @

Some of the Key Companies in the Usher Syndrome Market Include:

  • Sanofi

  • Neurotech Pharmaceuticals

  • Editas Medicine

  • Atsena Therapeutics

  • Nacuity Pharmaceuticals

  • ProQR Therapeutics

And others.

Usher Syndrome Therapies covered in the report include:

  • NT-501

  • QR-421a

  • UshStat (SAR421869)

And many more.

Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Usher Syndrome Competitive Intelligence Analysis

4. Usher Syndrome Market Overview at a Glance

5. Usher Syndrome Disease Background and Overview

6. Usher Syndrome Patient Journey

7. Usher Syndrome Epidemiology and Patient Population (In the US, EU5, and Japan)

8. Usher Syndrome Treatment Algorithm, Current Treatment, and Medical Practices

9. Usher Syndrome Unmet Needs

10. Key Endpoints of Usher Syndrome Treatment

11. Usher Syndrome Marketed Products

12. Usher Syndrome Emerging Drugs and Latest Therapeutic Advances

13. Usher Syndrome Seven Major Market Analysis

14. Attribute Analysis

15. Usher Syndrome Market Outlook (In US, EU5, and Japan)

16. Usher Syndrome Access and Reimbursement Overview

17. KOL Views on the Usher Syndrome Market

18. Usher Syndrome Market Drivers

19. Usher Syndrome Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF to Explore the Key Offerings of the Report @

Other Trending Healthcare Reports By DelveInsight

Usher Syndrome Pipeline Insight

“Usher Syndrome – Pipeline Insight, 2022,” report provides comprehensive insights about 5+ companies and 8+ drugs in Usher Syndrome pipeline landscape. It analyzes the pipeline drug profiles, including clinical and nonclinical stage products. Moreover, it also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. 

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States